William Chou, Passage Bio CEO
With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial
Passage Bio has passed through a rough stretch of layoffs, exec departures, and pipeline cuts this past year.
And with a new CEO in William …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
